Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions

Trial Profile

Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Nevirapine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Acronyms VENICE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jul 2010 Results have been presented at the 18th International AIDS Conference.
    • 10 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top